DXC Technology Co (DXC)

Nov 5, 2026

Shares of DXC Technology Co. (DXC) rose 1.95% to $15.17 on Thursday, defying a general market downturn where the S&P 500 Index and Dow Jones Industrial Average both experienced significant declines. This marks the second consecutive day of gains for the stock.

Nov 4, 2026

Zacks Research has downgraded DXC Technology (NYSE:DXC) from a "hold" to a "strong sell" rating. Despite beating earnings and revenue expectations in its latest quarter, the company saw a 4.1% year-over-year revenue decline, and its stock traded down 6.3% on Monday. Analyst consensus remains cautious with an average "Reduce" rating and a $12.06 price target.

Nov 3, 2026

DXC Technology (NYSE:DXC) shares declined 6.3% to $13.83, with trading volume significantly lower than average. Analyst sentiment is generally cautious, with a "Reduce" consensus rating and an average price target of $12.06, despite the company exceeding quarterly earnings and revenue estimates. While DXC reported adjusted EPS of $0.67 and $3.03 billion in revenue, revenue still saw a 4.1% year-over-year decrease.

Nov 2, 2026

DXC Technology Co. stock declined by 1.47% to $14.76 on Monday, underperforming the broader market. This marked the third consecutive day of losses for the company's shares. The Dow Jones Industrial Average rose while the S&P 500 Index fell during the same trading session.

Oct 30, 2026

DXC Technology's CEO, Raul Fernandez, has confirmed that the company is in talks to sell its insurance business unit. This unit, while only accounting for about 9% of overall revenue, is noted as the only business segment consistently posting growth for DXC. The potential sale comes amidst a broader turnaround effort for the company.

Oct 30, 2026

Shares of DXC Technology Co. (DXC) dropped 1.64% to $14.98 on Friday, underperforming major market indexes like the S&P 500 and Dow Jones Industrial Average, which also saw declines. This marked the stock's second consecutive day of losses.

Oct 30, 2026

DXC Technology reported mixed Q2 2027 results, with revenue exceeding guidance but adjusted EBIT and non-GAAP EPS declining year-over-year. The company confirmed ongoing discussions for a potential sale of its insurance business and adjusted its full-year guidance downwards due to weaker-than-expected sales performance in its core business and lower pipeline conversion rates, particularly in the Americas and UKI. Despite these challenges, DXC highlighted progress in its AI-based solutions, including significant AI certifications among its employees and strategic wins like a large banking sector contract for its GrowthX offering.